Showing results (161-170 of 221) with videos related to
Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|February 4, 2022
Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalitiesSepideh Azarianpour, Germán Corredor, Kaustav Bera, et al.Anti-Cancer Drugs|September 14, 2021
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancerPeter G Rose, Meng Yao, Laura M Chambers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2019
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II StudyPamela T Soliman, Shannon N Westin, David A Iglesias, et al.Antioxidants & Redox Signaling|July 19, 2024
A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer PrognosisGeorge Luo, Harshita Kumar, Kristin Aldridge, et al.Gynecologic Oncology|April 19, 2011
Disparities in treatment and survival between African American and White women with vaginal cancerHaider Mahdi, Sanjeev Kumar, Rabbie K Hanna, et al.Gynecologic Oncology|December 17, 2003
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesBrian M Slomovitz, Thomas W Burke, Patricia J Eifel, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancerLarissa A Meyer, Brian M Slomovitz, Bojana Djordjevic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinomaBrian M Slomovitz, Yunyun Jiang, Melinda S Yates, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.Gynecologic Oncology|December 17, 2014
Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution studyMohamed A Elshaikh, Zaid Al-Wahab, Haider Mahdi, et al.Pageof 23